Document 0080
 DOCN  M9490080
 TI    Immunogenicity of hybrid hepatitis B surface antigen particles.
 DT    9411
 AU    Mancini M; Schlienger K; Tiollais P; Michel ML; Unite de Recombinaison
       et Expression Genetique, Institut; Pasteur, Paris, France.
 SO    Int Rev Immunol. 1994;11(2):143-51. Unique Identifier : AIDSLINE
       MED/94321838
 AB    Hepatitis B surface antigen (HBsAg) produced by recombinant DNA
       technology is now widely and safely used worldwide for hepatitis B
       vaccination. We used the HBsAg particle as a carrier molecule for
       presentation of selected human immunodeficiency virus type 1 (HIV-1)
       determinants to the immune system. Immunization studies carried out in
       primates showed that the particles elicit HIV specific virus
       neutralizing antibodies as well as T cell proliferative responses to
       both pathogens. As an experimental approach to active immunotherapy for
       hepatitis B virus (HBV) chronic carriers, we evaluated the efficiency of
       such hybrid antigen to overcome B cell tolerance in HBV transgenic mice.
 DE    Amino Acid Sequence  Animal  AIDS Vaccines/*IMMUNOLOGY  Blotting,
       Western  Genetic Vectors/*IMMUNOLOGY  Hepatitis B Surface
       Antigens/*IMMUNOLOGY  Hepatitis B Vaccines/*IMMUNOLOGY  Molecular
       Sequence Data  Recombinant Fusion Proteins/*IMMUNOLOGY  Support,
       Non-U.S. Gov't  T-Lymphocytes/IMMUNOLOGY  Vaccines, Synthetic/IMMUNOLOGY
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).